EndoPredict al SABCS – Dati prospettici a lungo termine e in “real world” Dicembre 14, 2022 Due studi prospettici in “real world” presentati al SABCS mostrano che EndoPredict guida con precisione le decisioni relative alla chemioterapia nel tumore... Continue Reading
Guarda il simposio satellite dell’industria di Myriad Genetics all’ESMO 2022 Settembre 19, 2022 Dovremmo usare le firme genetiche per decidere la chemioterapia nelle pazienti ER+/HER2- in premenopausa? La dott.ssa Anastasia Constantinidou condivide i nuov... Continue Reading
EndoPredict informs treatment decisions for premenopausal breast cancer Agosto 31, 2022 New publication shows EndoPredict Breast Cancer Prognostic Test accurately identified premenopausal women with ER+, HER2- breast cancer who could safely avoid ... Continue Reading
High adherence to EndoPredict test results in extended endocrine therapy decision making in early breast cancer Giugno 22, 2022 Clinicians demonstrated up to 100% adherence to EndoPredict test results in extended endocrine therapy decision making As a leader in genetic testing and pr... Continue Reading